SAB Biotherapeutics (SABS) Earnings Date & Reports

Key Takeaways

• SAB Biotherapeutics posted a third-quarter 2026 net loss of $22.3 million, or $0.24 per share, narrower than the consensus estimate of a $0.27 loss.
• The clinical-stage biopharmaceutical company reported no revenue for the quarter, consistent with its pre-commercial status.
• Research and development (R&D) expenses climbed to $18.1 million from $9.0 million a year earlier, driven by the registrational SAFEGUARD study of SAB-142.
• Cash, cash equivalents, and investment securities totaled $205.3 million, which management says supports an operational runway through 2028.
• The adult and adolescent cohorts of the SAFEGUARD trial are fully enrolled, and the U.S. Food and Drug Administration (FDA) granted Fast Track designation to SAB-142.
• For more on SABS's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

SAB Biotherapeutics is developing SAB-142, a fully human anti-thymocyte globulin (hATG) immunotherapy intended to treat Stage 3 type 1 diabetes (T1D). Because the company has no approved products, its quarterly earnings are driven less by top-line revenue and more by clinical execution and cash management. Investors watch spending closely, but the real catalyst is the progress of the ~159-patient SAFEGUARD registrational study, with topline data expected in the second half of 2027. Against that backdrop, this report matters chiefly for what it reveals about enrollment, safety, and the company's financial runway to reach its next major data milestones.

Reported Results

For the third quarter ended September 30, 2026, SAB Biotherapeutics reported a net loss of $22.3 million, or $0.24 per share, beating the consensus estimate of a $0.27 loss. The company reported no revenue for the period, which is typical for a pre-commercial biotech.

Operating expenses rose as the SAB-142 program advanced. R&D expenses increased to $18.1 million from $9.0 million in the prior-year quarter, while general and administrative (G&A) expenses grew to $7.8 million from $3.7 million. A meaningful portion of both increases reflected non-cash stock-based compensation of roughly $7.5 million across the two categories, compared with about $0.8 million a year earlier.

The year-over-year comparison is distorted by a non-operating swing. In the prior-year quarter, the company reported net income of $45.4 million, driven largely by $58.1 million in other income tied to changes in the fair value of warrant liabilities. Stripping out that effect, the underlying cost trend is clearly higher, consistent with a company running a large registrational trial across more than 60 sites. Management reaffirmed guidance, leaving its cash runway through 2028 unchanged.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for investors tracking biotech names like SABS. Explore the AI Screener to streamline your market research.

Market Reaction and Investor Sentiment

Heading into the report, investor sentiment had improved modestly, and the narrower-than-expected loss offered a supportive, if secondary, signal. For a clinical-stage company, however, the EPS beat matters less than program execution. The market's focus has centered on SAFEGUARD enrollment progress, the pediatric step-down approval to ages 5–11 with no new safety signals, and the FDA's Fast Track designation for SAB-142. These milestones reinforce the credibility of the development timeline, though rising cash burn and the distance to the second-half 2027 topline readout remain key risk factors that could temper enthusiasm.

Forward Outlook and Key Factors to Monitor

Looking ahead, the primary catalysts are clinical rather than financial. Management reaffirmed that overall SAFEGUARD enrollment remains on track for completion in the fourth quarter of 2026, with topline data expected in the second half of 2027. The primary endpoint is preservation of beta cell function as measured by C-peptide, a marker of insulin production, alongside glycemic control metrics including HbA1c (a measure of average blood sugar) and continuous glucose monitoring data.

Investors will also watch the investigator-led PRISE-hATG Phase 3 trial, funded by Breakthrough T1D, which could extend the potential label to patients up to two years post-diagnosis. The first patient dosing was expected in the fourth quarter of 2026. The FDA's Fast Track designation for SAB-142 brings more frequent agency interaction and eligibility for rolling submission of a Biologics License Application (BLA), the formal request for marketing approval.

On the financial side, the key variable is spending discipline. Cash fell to $205.3 million from $217.6 million at the end of the prior quarter, even after $13.4 million in warrant-exercise proceeds. Management has said PRISE-related costs are already embedded in its burn guidance and reaffirmed runway through 2028. Investors should monitor the pace of quarterly operating losses against that runway, along with any updated disclosure on safety, redosing durability, and differentiation versus Tzield, the competing therapy now marketed for Stage 3 T1D.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations